NCT07285239
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07285239
Title Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (PrE1005)
Acronym PrE1005
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors PrECOG, LLC.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Gundersen Lutheran RECRUITING La Crosse Wisconsin 54601 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field